What is PathoVax?
PathoVax LLC is a private biotechnology startup founded by Johns Hopkins graduates Weijie Poh, Joshua Wang, and Nicholas Calcaterra. The company is focused on developing RGVax, a next-generation Human Papillomavirus (HPV) vaccine. RGVax aims to overcome the limitations of existing HPV vaccines, addressing issues such as incomplete protection, high manufacturing costs, and compliance challenges. The technology has already garnered support from the National Cancer Institute (NCI) for critical milestones, indicating strong scientific validation for its potential in a market segment valued at $2 billion annually.
How much funding has PathoVax raised?
PathoVax has raised a total of $79K across 1 funding round:
Debt
$79K
Debt (2021): $79K with participation from PPP
Key Investors in PathoVax
PPP
Public-Private Partnership
What's next for PathoVax?
With the recent influx of expansion capital, PathoVax is poised for significant growth and accelerated clinical testing of its RGVax vaccine. The company's strategic focus will likely involve scaling manufacturing capabilities, advancing through clinical trial phases, and forging partnerships to ensure rapid market uptake. The backing from inventors involved in current HPV vaccine development, coupled with NCI support, positions PathoVax to potentially disrupt the existing HPV vaccine market and capture a substantial share.
See full PathoVax company page
